Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Kiromic BioPharma completes license pact with Longwood University for chPD1 » 16:32
01/26/21
01/26
16:32
01/26/21
16:32
KRBP

Kiromic BioPharma

$9.08 /

+0.33 (+3.77%)

Kiromic BioPharma…

Kiromic BioPharma announced the completion of the chPD1 licensing agreement with Longwood University. "Longwood University is proud to have completed this chPD1 licensing agreement with Kiromic. We believe that Kiromic has a strong Allogenic Off-The-Shelf CAR-T program which will be even stronger with chPD1. The role that chPD1 plays in the modulation of the tumor micro-environment (TME) can never be underestimated when treating solid tumors," says Dr. Amorette Barber, PhD, Associate Professor of Biology and Director of the Office of Student Research at Longwood University. "The completion of the licensing agreement for chPD1 marks a major milestone for Kiromic CAR-T development. With chPD1, we believe our chimeric PD1 CAR-T will be able to overcome the challenging tumor micro-environment (TME) which has plagued other CAR-T programs," says Dr. Maurizio Chiriva-Internati, PhD, CEO of Kiromic BioPharma.

ShowHide Related Items >><<
KRBP Kiromic BioPharma
$9.08 /

+0.33 (+3.77%)

  • 16
    Oct
KRBP Kiromic BioPharma
$9.08 /

+0.33 (+3.77%)

Conference/Events
Kiromic BioPharma to host conference call » 15:55
01/21/21
01/21
15:55
01/21/21
15:55
KRBP

Kiromic BioPharma

$9.38 /

-0.07 (-0.74%)

Conference call with…

Conference call with management to be held on January 21 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
KRBP Kiromic BioPharma
$9.38 /

-0.07 (-0.74%)

  • 16
    Oct
KRBP Kiromic BioPharma
$9.38 /

-0.07 (-0.74%)

Conference/Events
Kiromic BioPharma to host conference call » 14:00
01/21/21
01/21
14:00
01/21/21
14:00
KRBP

Kiromic BioPharma

$9.37 /

-0.08 (-0.85%)

Conference call with…

Conference call with management to be held on January 21 at 4:15 pm. Webcast Link

ShowHide Related Items >><<
KRBP Kiromic BioPharma
$9.37 /

-0.08 (-0.85%)

  • 16
    Oct
KRBP Kiromic BioPharma
$9.37 /

-0.08 (-0.85%)

Hot Stocks
Kiromic BioPharma announces completion, certification of Houston facility » 05:32
01/20/21
01/20
05:32
01/20/21
05:32
KRBP

Kiromic BioPharma

$8.70 /

+0.31 (+3.69%)

Kiromic BioPharma…

Kiromic BioPharma announced the completion and certification of its GMP facility in Houston, Texas. GMP facility construction is complete and certified to meet all FDA required regulatory guidelines. GMP facility is ready to support the company's upcoming first in-human, off-the-shelf, allogenic CAR-T trial. The CAR-T ovarian cancer trials will have these targets: chPD1 Gamma-Delta and anti-ISOMSLN. Gamma-Delta-T cell GMP manufacturing test batch optimization and qualification studies are proceeding as scheduled.

ShowHide Related Items >><<
KRBP Kiromic BioPharma
$8.70 /

+0.31 (+3.69%)

  • 16
    Oct
KRBP Kiromic BioPharma
$8.70 /

+0.31 (+3.69%)

Hot Stocks
Kiromic BioPharma submits to IND applications for CAR-T cell therapy with FDA » 12:46
12/17/20
12/17
12:46
12/17/20
12:46
KRBP

Kiromic BioPharma

$10.99 /

+1.42 (+14.84%)

Kiromic BioPharma…

Kiromic BioPharma announced the submission of two investigational new drug applications with the U.S. Food and Drug Administration for the initiation of: Phase 1 clinical trial of an intravenously administered allogenic CAR-T for epithelial ovarian carcinoma and malignant pleural mesothelioma and; Phase 1 clinical trial of an intrapleural/intraperitoneal administered allogenic CAR-T for EOC and MPM. Kiromic's proprietary PD1 Gamma-delta CAR-T cell therapy is a novel method for "off-the-shelf" allogeneic CAR T cells derived from healthy donors. We believe our proprietary gamma-delta T cell manufacturing and distribution will offer significant advantages over competitive manufacturing technologies. The initial dose escalation component of each CAR-T trial is projected to enroll approximately 12 patients over 4 months at two sites. The first in-human dosing is targeted for 1Q-2021.

ShowHide Related Items >><<
  • 16
    Oct
KRBP Kiromic BioPharma
$10.99 /

+1.42 (+14.84%)

Over a quarter ago
On The Fly
Opening Day: Array jumps after $1.05B IPO » 09:01
10/18/20
10/18
09:01
10/18/20
09:01
OAK

Oaktree Capital

$51.58 /

+ (+0.00%)

, TCEHY

Tencent

$0.00 /

+ (+0.00%)

, PRAX

Praxis Precision Medicines

$28.00 /

+ (+0.00%)

, EAR

Eargo

$33.80 /

+ (+0.00%)

, ALGS

Aligos Therapeutics

$14.93 /

+ (+0.00%)

, KRBP

Kiromic BioPharma

$11.50 /

+ (+0.00%)

, OPT

Opthea

$12.50 /

+ (+0.00%)

, TARS

Tarsus Pharmaceuticals

$20.48 /

+ (+0.00%)

, ARRY

Array Technologies

$38.76 /

+2.34 (+6.43%)

, MNSO

Miniso

$23.49 /

+2.81 (+13.59%)

, EBC

Eastern Bankshares

$11.93 /

-0.16 (-1.32%)

, CDAK

Codiak

$12.20 /

-0.6 (-4.69%)

, TMPM

Turmeric Acquisition

$0.00 /

+ (+0.00%)

, BTWN

Bridgetown Holdings

$0.00 /

+ (+0.00%)

, TMTS

Spartacus Acquisition

$0.00 /

+ (+0.00%)

, AIRB

Use ABNB

$0.00 /

+ (+0.00%)

, IKT

Inhibikase Therapeutics

$0.00 /

+ (+0.00%)

, MCFE

McAfee

$0.00 /

+ (+0.00%)

Shares of Oaktree-backed…

ShowHide Related Items >><<
TCEHY Tencent
$0.00 /

+ (+0.00%)

EBC Eastern Bankshares
$11.93 /

-0.16 (-1.32%)

AIRB Use ABNB
$0.00 /

+ (+0.00%)

OAK Oaktree Capital
$51.58 /

+ (+0.00%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

10/14/20 OTR Global
Tencent upgraded to Positive from Mixed at OTR Global
08/13/20 Benchmark
Tencent price target raised to HK$575 from HK$560 at Benchmark
08/03/20 Morgan Stanley
Sohu.com named a Research Tactical Idea at Morgan Stanley
07/27/20 Barclays
Tencent price target raised to $75 from $63 at Barclays
PRAX Praxis Precision Medicines
$28.00 /

+ (+0.00%)

EAR Eargo
$33.80 /

+ (+0.00%)

ALGS Aligos Therapeutics
$14.93 /

+ (+0.00%)

KRBP Kiromic BioPharma
$11.50 /

+ (+0.00%)

OPT Opthea
$12.50 /

+ (+0.00%)

TARS Tarsus Pharmaceuticals
$20.48 /

+ (+0.00%)

ARRY Array Technologies
$38.76 /

+2.34 (+6.43%)

MNSO Miniso
$23.49 /

+2.81 (+13.59%)

EBC Eastern Bankshares
$11.93 /

-0.16 (-1.32%)

10/15/20 Janney Montgomery Scott
Eastern Bankshares initiated with a Buy at Janney Montgomery Scott
10/08/20 Compass Point
Eastern Bankshares initiated with a Buy at Compass Point
CDAK Codiak
$12.20 /

-0.6 (-4.69%)

TMPM Turmeric Acquisition
$0.00 /

+ (+0.00%)

BTWN Bridgetown Holdings
$0.00 /

+ (+0.00%)

TMTS Spartacus Acquisition
$0.00 /

+ (+0.00%)

AIRB Use ABNB
$0.00 /

+ (+0.00%)

IKT Inhibikase Therapeutics
$0.00 /

+ (+0.00%)

MCFE McAfee
$0.00 /

+ (+0.00%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

  • 16
    Oct
  • 15
    Oct
  • 22
    Oct
  • 16
    Oct
  • 16
    Oct
  • 16
    Oct
  • 16
    Oct
  • 16
    Oct
  • 15
    Oct
  • 14
    Oct
  • 15
    Oct
TCEHY Tencent
$0.00 /

+ (+0.00%)

OAK Oaktree Capital
$51.58 /

+ (+0.00%)

AIRB Use ABNB
$0.00 /

+ (+0.00%)

TCEHY Tencent
$0.00 /

+ (+0.00%)

ARRY Array Technologies
$38.76 /

+2.34 (+6.43%)

AIRB Use ABNB
$0.00 /

+ (+0.00%)

Syndicate
Kiromic BioPharma opens at $11.80, IPO priced at $12 per share » 12:01
10/16/20
10/16
12:01
10/16/20
12:01
KRBP

Kiromic BioPharma

$0.00 /

+ (+0.00%)

Kiromic BioPharma (KRBP)…

Kiromic BioPharma (KRBP) priced 1.25M shares at $12.00. ThinkEquity acted as sole book running manager for the offering.

ShowHide Related Items >><<
  • 16
    Oct
Syndicate
Kiromic BioPharma 1.25M share IPO priced at $12.00 » 17:52
10/15/20
10/15
17:52
10/15/20
17:52
KRBP

Kiromic BioPharma

$0.00 /

+ (+0.00%)

ThinkEquity acted as sole…

ThinkEquity acted as sole book running manager for the offering.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.